Skip to main content
BIXT
OTC Life Sciences

Bioxytran Q3: $74K Cash, Going Concern, Defaulted Note and New Lawsuit

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.022
Mkt Cap
$2.523M
52W Low
$0.02
52W High
$0.095
52W Position info
10.0% above low
Off High info
77% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

BIXT is trading near its 52-week low of $0.02 (10.0% above the low).

Summary

Bioxytran's Q3 10-Q shows $74,369 of cash, a $6.38M working-capital deficit and a going-concern warning, with its 2021 convertible note still in default and a new $1.35M lawsuit from a former officer.


Key Events · Earnings and Guidance · BIXT

  • Going Concern With $74K Cash

    Cash stood at $74,369 on September 30, 2026, down from $509,914 at December 31, 2025, with negative working capital of $6,381,654 and an accumulated deficit of $25,011,000.

  • Nine-Month Loss Widens to $3.97M

    The nine-month net loss reached $3,966,754 versus $1,600,922 a year earlier, driven largely by a $964,994 non-cash change in fair value of the embedded derivative and a $1,278,600 stock-based CEO performance grant.

  • Convertible Note Still in Default

    The 2021 Note carries $805,000 principal plus $386,333 accrued interest, has been in default since March 1, 2025 at an 18% default rate, and its derivative liability stands at $1,368,347, above the note's own principal.

  • New $1.35M Lawsuit From Ex-Officer

    Served October 6, 2026 in Nevada, the suit seeks $1,346,000 in wrongful-termination pay, challenges lock-up of 41,073,600 common-equivalent shares and the 30,000,000-share CEO grant, and seeks to halt nutraceutical sales; no accrual has been recorded.


Analysis · BIXT · Life Sciences

Bioxytran closed September 30, 2026 with just $74,369 of cash against $6.46M of current liabilities, leaving a $6.38M working-capital hole, and management again warns that these conditions raise substantial doubt about its ability to continue as a going concern. Only $322,423 was raised in the nine months through private placements, while the company says it needs roughly $3.7M to fund 15 months of operations, so survival hinges on selling more stock into a $0.022 share price. The $805,000 2021 convertible note has been in default since March 1, 2025 at an 18% default rate, and its embedded derivative now sits at $1,368,347, larger than the note itself, after a $964,994 non-cash mark-to-market charge that drove most of the $3.97M nine-month loss. On top of that, a new Nevada lawsuit from a fired officer seeks $1,346,000 in termination pay and challenges the 30,000,000-share (common-equivalent) grant to the CEO, while a material weakness in internal controls has been reaffirmed.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BIXT was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.02 to $0.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BIXT - Latest Insights

BIXT
Aug 14, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.021
Real-time Price: $0.022 info
Change: +$0.0010 (+5%) info
Market Cap: $2.523M info
BIXT
Aug 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0214
Real-time Price: $0.022 info
Change: +$0.0006 (+3%) info
Market Cap: $2.523M info
BIXT
May 15, 2026, 1:28 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.033
Real-time Price: $0.022 info
Change: -$0.011 (-33%) info
Market Cap: $2.523M info
BIXT
Apr 15, 2026, 4:01 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $0.037
Real-time Price: $0.022 info
Change: -$0.015 (-41%) info
Market Cap: $2.523M info
BIXT
Mar 20, 2026, 9:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.0362
Real-time Price: $0.022 info
Change: -$0.0142 (-39%) info
Market Cap: $2.523M info